Stanislav Glezer
Director/Board Member bei Diabetes Foundation of New Jersey
Vermögen: 207 678 $ am 30.04.2024
Aktive Positionen von Stanislav Glezer
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| Diabetes Foundation of New Jersey | Director/Board Member | 24.07.2019 | - |
Karriereverlauf von Stanislav Glezer
Ehemalige bekannte Positionen von Stanislav Glezer
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| INOGEN, INC. | Chief Tech/Sci/R&D Officer | 21.06.2021 | 03.05.2024 |
| BECTON, DICKINSON AND COMPANY | Chief Tech/Sci/R&D Officer | 01.09.2018 | 01.06.2021 |
| ADOCIA | Chief Tech/Sci/R&D Officer | 26.07.2017 | 01.05.2018 |
Novo Nordisk, Inc.
 Novo Nordisk, Inc. BiotechnologyHealth Technology Novo Nordisk, Inc. operates diabetes care company. It offers biopharmaceuticals, chronic weight management, human growth hormone therapy and hemophilla management services. The firm also provides rare bleeding disorders, growth hormone related disorders, and women's health. The company was founded in 1982 and is headquartered in Plainsboro, NJ. | Chief Tech/Sci/R&D Officer | 01.03.2016 | 01.03.2017 |
| Sanofi SA | Corporate Officer/Principal | - | - |
Ausbildung von Stanislav Glezer
| California Coast University | Masters Business Admin |
| Yevdokimov MSUMD | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 6 |
| Frankreich | 3 |
| Russland | 2 |
Operativ
| Chief Tech/Sci/R&D Officer | 4 |
| Doctorate Degree | 1 |
| Masters Business Admin | 1 |
Sektoral
| Health Technology | 6 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| BECTON, DICKINSON AND COMPANY | Health Technology |
| INOGEN, INC. | Health Technology |
| ADOCIA | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Novo Nordisk, Inc.
Novo Nordisk, Inc. BiotechnologyHealth Technology Novo Nordisk, Inc. operates diabetes care company. It offers biopharmaceuticals, chronic weight management, human growth hormone therapy and hemophilla management services. The firm also provides rare bleeding disorders, growth hormone related disorders, and women's health. The company was founded in 1982 and is headquartered in Plainsboro, NJ. | Health Technology |
| Sanofi SA | Health Technology |
| Diabetes Foundation of New Jersey |
- Börse
- Insiders
- Stanislav Glezer
- Erfahrung
